| |
| |
|
| Insider
Information: |
Vivaldi Coelho Rogerio |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
71,383 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,640,156 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
71,383 |
|
|
| Total
Value |
$2,640,156 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 84.3%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Minerva Neurosciences, Inc. |
NERV |
President and CEO, Dir... |
2014-07-01 |
41,667 |
2014-07-01 |
0 |
Premium* |
|
|
Spark Therapeutics, Inc. |
ONCE |
Chief Commercial Officer |
2016-07-15 |
18,716 |
|
0 |
Premium* |
|
|
Bioverativ Inc. |
BIVV |
EVP, Chief Global Ther... |
2018-03-08 |
0 |
2018-02-14 |
0 |
Premium* |
|
|
Sigilon Therapeutics, Inc. |
SGTX |
|
2023-08-11 |
0 |
2020-12-08 |
0 |
Premium* |
|
|
Crinetics Pharmaceuticals, Inc. |
CRNX |
Director |
2023-06-16 |
11,000 |
2023-06-08 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
22 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SGTX |
Sigilon Therapeutics, Inc... |
PRESIDENT AND CEO |
• • – |
2023-08-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(12,169) |
0 |
0 |
- |
|
| SGTX |
Sigilon Therapeutics, Inc... |
PRESIDENT AND CEO |
• • – |
2023-07-21 |
4 |
OE |
$19.24 |
$106,359 |
D/D |
5,528 |
11,963 |
0 |
- |
|
| CRNX |
Crinetics Pharmaceuticals... |
Director |
– • – |
2023-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
11,000 |
0 |
- |
|
| CRNX |
Crinetics Pharmaceuticals... |
Director |
– • – |
2023-06-08 |
4 |
B |
$22.06 |
$110,300 |
D/D |
5,000 |
5,000 |
2.39 |
% |
|
| SGTX |
Sigilon Therapeutics, Inc... |
PRESIDENT AND CEO |
• • – |
2021-11-04 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
73,461 |
0 |
- |
|
| SGTX |
Sigilon Therapeutics, Inc... |
President and CEO |
• • – |
2020-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
22,222 |
22,222 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
EVP, Chief Global Therapeutics |
• • – |
2018-03-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,758) |
0 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
EVP, Chief Global Therapeutics |
• • – |
2018-02-14 |
4 |
D |
$103.52 |
$220,084 |
D/D |
(2,126) |
5,303 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
EVP, Chief Global Therapeutics |
• • – |
2018-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,114 |
7,429 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial Officer |
• – – |
2016-07-15 |
4 |
AS |
$52.96 |
$371,224 |
D/D |
(7,000) |
18,716 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial Officer |
• – – |
2016-07-15 |
4 |
OE |
$3.45 |
$44,400 |
D/D |
7,000 |
25,716 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial Officer |
• – – |
2016-04-21 |
4 |
AS |
$40.02 |
$48,024 |
D/D |
(1,200) |
18,716 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial Officer |
• – – |
2016-04-21 |
4 |
OE |
$3.45 |
$4,950 |
D/D |
1,200 |
19,916 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial Officer |
• – – |
2016-04-20 |
4 |
AS |
$40.02 |
$232,116 |
D/D |
(5,800) |
18,716 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial Officer |
• – – |
2016-04-20 |
4 |
OE |
$3.45 |
$39,450 |
D/D |
5,800 |
24,516 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial Officer |
• – – |
2015-10-13 |
4 |
OE |
$7.50 |
$279,998 |
D/D |
37,333 |
42,716 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial Officer |
• – – |
2015-10-13 |
4 |
S |
$48.15 |
$1,155,600 |
D/D |
(24,000) |
18,716 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial Officer |
• – – |
2015-10-07 |
4 |
S |
$48.81 |
$2,002,800 |
D/D |
(41,000) |
5,383 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial Officer |
• – – |
2015-10-07 |
4 |
OE |
$3.45 |
$259,500 |
D/D |
40,000 |
46,383 |
0 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial Officer |
• – – |
2015-02-04 |
4 |
B |
$23.00 |
$57,500 |
D/D |
2,500 |
6,383 |
2.74 |
- |
|
| ONCE |
Spark Therapeutics, Inc. |
Chief Commercial OfficerOffice |
• – – |
2015-01-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,883 |
|
- |
|
| NERV |
Minerva Neurosciences, In... |
President and CEO |
• • – |
2014-07-01 |
4 |
B |
$6.00 |
$250,002 |
D/D |
41,667 |
41,667 |
2.81 |
- |
|
22 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
